Clinical Trials
10 trialsNCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT03151811 2024-01-30
OCEAN
Oncopeptides AB
Phase 3 Terminated
NCT02294357 2023-11-01
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Oncotherapeutics
Phase 2 Terminated
NCT03481556 2022-12-19
ANCHOR
Oncopeptides AB
Phase 1/2 Terminated
NCT01464034 2022-08-01
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Criterium, Inc.
Phase 1/2 Terminated
NCT01455389 2022-03-02
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Genprex, Inc.
Phase 1/2 Terminated
NCT02036502 2021-04-08
MK-3475-023
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02720510 2018-07-24
PANORAMA4
Novartis
Phase 2 Terminated
NCT00609817 2013-06-25
Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma
La Jolla Pharmaceutical Company
Phase 1 Terminated
NCT00474188 2009-09-02
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Terminated